Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.37 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30302088 | 1.00 | MGLL (0.46) | MGLLGPR119TACR1SYKBIRC5 | |
| SCHEMBL25487286 | 0.89 | GPR119 (0.43) | MGLLGPR119HCRTR1HCRTR2CYP2C9 | |
| SCHEMBL20571133 | 0.89 | MGLL (0.47) | MGLLHCRTR1HCRTR2CYP2C9 | |
| SCHEMBL30302141 | 0.86 | MGLL (0.55) | MGLL | |
| SCHEMBL20567198 | 0.86 | MGLL (0.55) | MGLL | |
| SCHEMBL23015503 | 0.83 | MGLL (0.41) | MGLLGPR119HCRTR1HCRTR2CYP2C9 | |
| SCHEMBL20566604 | 0.81 | MGLL (0.67) | MGLL | |
| SCHEMBL20567721 | 0.81 | MGLL (0.50) | MGLLGPR119TACR1BIRC5EPHX2 | |
| SCHEMBL20769762 | 0.80 | MGLL (0.46) | MGLLGPR119TACR1BIRC5EPHX2 | |
| SCHEMBL30487783 | 0.80 | MGLL (0.46) | MGLLGPR119TACR1BIRC5EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258340-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2025-03-25 | — | — | US | disclosed |
| CN-116473965-A | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| EP-4198024-A1 | PYRAZOLE MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2023-06-21 | — | — | EP | disclosed |
| EP-4198024-A1 | PYRAZOLE MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2023-06-21 | — | — | EP | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| CN-110678456-B | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-3630744-B1 | PYRAZOLE MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-01-25 | — | — | EP | disclosed |
| EP-3630744-B1 | PYRAZOLE MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-01-25 | — | — | EP | disclosed |
| US-20210053960-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2021-02-25 | — | — | US | disclosed |
| US-20210053960-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2021-02-25 | — | — | US | disclosed |
| US-10927105-B1 | Pyrazole MAGL inhibitors | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10927105-B1 | Pyrazole MAGL inhibitors | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3630744-A1 | PYRAZOLE MAGL INHIBITORS | Lundbeck La Jolla Research Center, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10266497-B2 | Pyrazole MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266497-B2 | Pyrazole MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180339970-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-11-29 | — | — | US | disclosed |
| WO-2018217805-A1 | PYRAZOLE MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180339970-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | MGLL 1/4885GPR119 308/4885TACR1 3648/4885 |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | MGLL 1/4885GPR119 308/4885TACR1 3648/4885 |
| US-12258340-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | MGLL 1/4885GPR119 353/4885TACR1 3847/4885 |
| US-10266497-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | MGLL 1/4885GPR119 308/4885TACR1 3648/4885 |
| US-20210053960-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | MGLL 1/4885GPR119 308/4885TACR1 3648/4885 |
| US-11655217-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | MGLL 1/4885GPR119 353/4885TACR1 3847/4885 |
| US-10927105-B1 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | MGLL 1/4885GPR119 308/4885TACR1 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.